immun
challeng
group
five
ferret
without
antibodi
circul
influenza
strain
immun
one
season
inactiv
split
vaccin
fluvir
glaxosmithklin
coldadapt
live
attenu
vaccin
flumist
medimmun
swine
influenza
vaccin
flusur
pfizer
match
laboratoryproduc
inactiv
vaccin
latter
vaccin
consist
madindarbi
canin
kidney
mdck
cellproduc
wholeviru
prepar
amexico
isol
ongo
influenza
outbreak
purifi
ultracentrifug
subsequ
inactiv
addit
formalin
final
concentr
incub
day
fisher
scientif
anim
receiv
recommend
dose
respect
commerci
vaccin
dose
contain
hemagglutinin
ha
experiment
vaccin
except
flumist
inocul
intranas
vaccin
inject
gluteal
muscl
recommend
dose
human
pig
respect
five
week
later
anim
challeng
intranas
tissu
cultur
infecti
dose
clinic
sign
bodi
temperatur
weight
assess
daili
anim
euthan
base
clinic
evalu
end
studi
day
viru
quantif
patholog
nasal
wash
collect
day
challeng
viru
titer
quantifi
limit
dilut
brief
serial
dilut
incub
mdck
cell
replic
per
dilut
h
infect
plate
score
cytopath
effect
viru
titer
calcul
use
method
reed
muench
rna
isol
viral
copi
number
quantifi
use
realtim
reversetranscript
polymeras
chain
reaction
rtpcr
tissu
preserv
rnalat
homogen
use
bead
mill
homogen
extract
total
rna
rna
isol
nasal
wash
swab
use
qiaamp
viral
rna
mini
kit
qiagen
tissu
use
rneasi
mini
kit
qiagen
viru
detect
quantit
realtim
rtpcr
perform
use
lightcycl
rna
master
hydrolysi
probe
roch
assay
target
ha
gene
nucleotid
posit
genbank
access
number
reaction
condit
follow
min
cycl
use
lightcycl
roch
low
detect
limit
assay
pfuml
primer
sequenc
follow
haf
ggatcaagaagggagaatgaactatt
har
aatgcatatctcggtaccactagattt
hap
ccgggagacaaaataacattcgaagcaac
euthanasia
necropsi
perform
anim
photograph
lung
taken
lung
harvest
histopatholog
analysi
lung
inflat
slow
inject
ml
phosphatebuff
salin
pb
invitrogen
trachea
formalinfix
paraffin
embed
tissu
section
stain
hematoxylineosin
immun
respons
assess
serum
sampl
collect
day
vaccin
analyz
presenc
hemagglutinationinhibit
hai
antibodi
season
strain
hai
antibodi
titer
express
reciproc
highest
serum
dilut
inhibit
hemagglutin
turkey
red
blood
cell
day
vaccin
heparin
blood
collect
prolifer
assay
brief
peripher
blood
mononuclear
cell
isol
ficollhypaqu
ge
healthcar
gradient
purif
cultiv
presenc
overlap
peptid
pool
cover
nucleocapsid
np
neuraminidas
na
ha
protein
relat
strain
abrevig
prolifer
respons
measur
ad
brdu
peptideexpos
peripher
blood
mononuclear
cell
h
next
day
cell
fix
brdu
incorpor
quantifi
immunostain
perform
use
chemoluminesc
substrat
roch
prolifer
index
express
ratio
brdu
incorpor
measur
respect
influenza
peptid
pool
ebola
viru
peptid
neg
control
messeng
rna
profil
cytokin
includ
interferon
ifn
interleukin
il
gener
nasal
wash
rna
isol
day
infect
rna
isol
right
left
lung
respect
anim
euthan
day
assay
perform
use
primer
method
outlin
elsewher
failur
season
vaccin
elicit
hai
antibodi
recogn
pandem
viru
hai
antibodi
titer
kinet
monitor
day
immun
titer
reciproc
dilut
remain
refer
standard
predict
protect
immun
elicit
influenza
vaccin
candid
hai
antibodi
titer
pandem
isol
detect
day
ferret
receiv
laboratoryproduc
match
vaccin
swine
influenza
vaccin
flusur
reach
titer
day
respect
flusur
gener
detect
hai
antibodi
titer
season
strain
includ
convent
season
influenza
vaccin
fluvir
flumist
contrast
day
day
season
vaccin
elicit
hai
antibodi
titer
wherea
crossreact
respons
detect
challeng
figur
none
vaccin
elicit
ifn
enzymelink
immunospot
respons
upon
stimul
overlap
peptid
cover
np
na
ha
protein
strain
abrevig
protein
share
amino
acid
ident
respect
protein
may
contribut
weak
respons
observ
howev
increas
prolifer
activ
respons
np
peptid
pool
detect
anim
immun
flumist
indic
crossreact
cell
respons
figur
correl
presenc
hai
antibodi
milder
diseas
improv
surviv
upon
intranas
challeng
vaccin
anim
display
delay
onset
fever
follow
cours
compar
nonvaccin
control
figur
clinic
anim
immun
swine
vaccin
flusur
demonstr
complet
protect
mild
transient
sign
diseas
less
weight
loss
first
week
group
surviv
match
vaccin
also
result
reduc
weight
loss
clinic
sign
diseas
improv
surviv
rate
compar
observ
naiv
control
figur
contrast
statist
signific
differ
record
clinic
sign
diseas
weight
loss
surviv
rate
anim
given
fluvir
control
group
cours
experi
challeng
p
group
ferret
vaccin
flumist
show
slight
improv
averag
bodi
weight
day
challeng
howev
weight
loss
increas
day
day
point
clinic
sign
diseas
includ
nasal
seromuc
exud
shallow
labor
breath
reduc
activ
forc
euthanasia
anim
given
flumist
result
small
increas
mortal
rate
compar
note
unvaccin
control
group
increas
mortal
rate
associ
mismatch
flumist
immun
also
observ
second
experi
anim
although
increas
statist
signific
data
shown
respect
time
euthanasia
gross
patholog
evalu
lung
demonstr
minim
lesion
anim
vaccin
flusur
includ
anim
euthan
day
without
reach
experiment
end
point
obtain
time
basi
tissu
sampl
match
obtain
group
figur
anim
vaccin
show
slight
improv
smaller
lesion
note
ferret
three
control
anim
sever
lesion
hepat
hemorrhag
widespread
alveol
bronchiol
compar
lesion
observ
ferret
vaccin
fluvir
flumist
respect
associ
protect
lower
infecti
viral
load
earli
infect
group
reach
nasal
infecti
titer
day
challeng
except
anim
immun
swine
vaccin
flusur
lower
titer
figur
group
vaccin
flumist
maintain
rel
high
level
viru
replic
day
wherea
group
experienc
titer
decreas
except
one
anim
control
group
infecti
viral
particl
detect
titrat
nasal
wash
anim
day
later
although
viral
rna
could
detect
realtim
rtpcr
end
experi
figur
correl
moder
level
nasal
wash
cell
day
infect
partial
protect
anim
immun
flusur
experienc
lowest
ifn
level
upregul
ifn
earli
stage
infect
moder
elev
level
detect
later
cours
day
exclus
group
show
evid
protect
figur
contrast
group
vaccin
flumist
exhibit
highest
averag
mrna
transcript
day
day
possibl
reflect
better
cellular
respons
interest
day
level
transcript
significantli
higher
upper
airway
anim
vaccin
flumist
day
infect
slightli
increas
lower
airway
compar
observ
control
anim
anim
vaccin
flusur
figur
differ
tumor
necrosi
factor
level
observ
group
data
shown
avail
effici
vaccin
essenti
allevi
effect
ongo
influenza
pandem
possibl
intervent
strategi
mitig
fall
influenza
season
northern
hemispher
initi
perform
mass
immun
season
vaccin
follow
mass
immun
fulli
match
pandem
vaccin
soon
would
becom
avail
direct
concert
public
health
respons
control
spread
viru
efficaci
newli
produc
match
inactiv
vaccin
well
alreadi
avail
inactiv
live
attenu
vaccin
assess
toward
end
compar
antibodi
cellular
respons
elicit
season
vaccin
fluvir
flumist
commerci
swine
vaccin
flusur
laboratoryproduc
match
inactiv
wholeviru
prepar
found
swine
match
vaccin
result
product
hai
antibodi
pandem
viru
wherea
flumist
trigger
crossreact
cellular
respons
intranas
challeng
virul
mexican
isol
similar
also
lead
mortal
rate
among
naiv
anim
reveal
none
vaccin
abl
confer
complet
protect
one
immun
howev
flusur
associ
best
reduct
morbid
complet
protect
mortal
wherea
match
inactiv
vaccin
result
moder
clinic
improv
reduc
mortal
expect
undetect
hai
antibodi
titer
anim
vaccin
fluvir
flumist
experi
benefici
effect
compar
unvaccin
control
anim
partial
protect
observ
anim
vaccin
one
dose
match
inactiv
vaccin
despit
detect
hai
antibodi
respons
within
protect
rang
indic
protect
aggress
isol
may
requir
singl
immun
would
put
addit
strain
vaccin
avail
use
virul
challeng
strain
enabl
assess
vaccin
efficaci
worstcas
scenario
howev
diseas
sever
associ
current
circul
pandem
strain
patient
similar
associ
season
influenza
thu
possibl
singl
dose
match
inactiv
vaccin
suffici
confer
protect
pandem
strain
especi
individu
level
crossprotect
due
previou
influenza
infect
effici
commerci
avail
swine
vaccin
indic
product
would
adequ
protect
anim
includ
pig
herd
could
minim
interspeci
transmiss
mayb
limit
evolut
viru
flusur
vaccin
consist
inactiv
type
field
isol
formul
amphigen
pfizer
adjuv
indic
use
adjuv
merit
indepth
evalu
context
develop
improv
human
influenza
vaccin
curiou
observ
sever
case
diseas
higher
mortal
rate
note
anim
vaccin
flumist
correl
slightli
infecti
viru
nasal
wash
group
day
correl
infecti
viral
load
upper
respiratori
tract
clinic
outcom
fact
observ
group
present
studi
confirm
previou
report
infecti
viral
load
airway
predict
level
protect
vaccin
ferret
challeng
respiratori
virus
includ
sever
acut
respiratori
syndromeassoci
coronaviru
influenza
hand
data
studi
also
indic
weight
loss
averag
sever
unvaccin
control
anim
vaccin
group
anim
present
studi
design
evalu
protect
efficaci
vaccin
possibl
subtl
neg
effect
caus
immun
mismatch
influenza
antigen
larger
studi
group
size
necessari
conclus
address
question
appropri
degre
statist
confid
antibodymedi
enhanc
influenza
infect
includ
subtypecrossreact
nonneutr
antibodi
previous
describ
cultur
cell
mechan
never
directli
associ
worsen
clinic
condit
anim
model
influenza
infect
although
recent
studi
report
matern
deriv
antibodi
possibl
enhanc
swine
influenza
virusinduc
pneumonia
pig
observ
support
need
detail
evalu
efficaci
influenza
vaccin
control
experiment
condit
variou
level
preexist
immun
mismatch
influenza
antigen
could
studi
anim
demonstr
strong
induct
proinflammatori
cytokin
day
level
remain
elev
day
group
ferret
show
notic
protect
anim
vaccin
flumist
group
mount
strong
crossreact
cellular
respons
highest
ifn
respons
howev
respons
suffici
control
diseas
fact
strong
express
antiinflammatori
cytokin
detect
group
day
may
suppress
appropri
inflammatori
respons
includ
express
temporarili
favor
viru
replic
previous
demonstr
pig
infect
footandmouth
diseas
report
show
neg
effect
influenza
virusinfect
mice
pig
increas
product
correl
low
antibodi
respons
elderli
individu
influenza
vaccin
evalu
respons
cytokin
includ
earli
time
point
patient
may
help
predict
unfavor
outcom
allow
better
alloc
resourc
individu
requir
intens
clinic
intervent
present
studi
report
immun
respons
protect
efficaci
commerci
avail
vaccin
one
laboratoryproduc
match
vaccin
regard
prevent
pandem
infect
ferret
find
studi
may
help
guid
ongo
prepar
influenza
season
northern
hemispher
